View in EDS HTML Full Text PDF Full Text

Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.

Saved in:
Bibliographic Details
Title: Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.
Authors: Ding, Lu1 (AUTHOR), Nuersulitan, Reyizha1 (AUTHOR), Wang, Jingjing1 (AUTHOR), Chen, Hanxiao1 (AUTHOR), Zhuo, Minglei1 (AUTHOR) zhuominglei@bjmu.edu.cn
Source: Current Oncology. May2026, Vol. 33 Issue 5, p258. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 194129130
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Ding%2C+Lu%22">Ding, Lu</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nuersulitan%2C+Reyizha%22">Nuersulitan, Reyizha</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Jingjing%22">Wang, Jingjing</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+Hanxiao%22">Chen, Hanxiao</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhuo%2C+Minglei%22">Zhuo, Minglei</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> zhuominglei@bjmu.edu.cn</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Current+Oncology%22">Current Oncology</searchLink>. May2026, Vol. 33 Issue 5, p258. 10p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=194129130
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/curroncol33050258
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 258
    Titles:
      – TitleFull: Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ding, Lu
      – PersonEntity:
          Name:
            NameFull: Nuersulitan, Reyizha
      – PersonEntity:
          Name:
            NameFull: Wang, Jingjing
      – PersonEntity:
          Name:
            NameFull: Chen, Hanxiao
      – PersonEntity:
          Name:
            NameFull: Zhuo, Minglei
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 11980052
          Numbering:
            – Type: volume
              Value: 33
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Current Oncology
              Type: main
ResultId 1